International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.12778899
Original Research Article
Efficacy of Fractional CO2 Laser Therapy in the Management of Hypertrophic Scars: A Clinical Study
Published
Nov. 5, 2024
Abstract

Background: Hypertrophic scarring presents a significant therapeutic challenge in dermatologic practice. Fractional CO₂ laser therapy has emerged as a promising treatment modality, yet comprehensive clinical data remains limited. Objective: To evaluate the efficacy and safety of fractional CO₂ laser therapy in the management of hypertrophic scars through objective and subjective parameters. Methods: Forty-five patients with hypertrophic scars underwent three sessions of fractional CO₂ laser treatment at 6-week intervals. Outcomes were assessed using Vancouver Scar Scale (VSS), digital caliper measurements, standardized photographs, patient-reported outcomes, and independent observer evaluation. Results: Mean scar thickness decreased from 3.8 ± 0.9 mm to 2.0 ± 0.5 mm (47.4% reduction, p<0.001), as measured by digital caliper with high inter-observer reliability (ICC: 0.91-0.94). Total VSS scores improved from 9.8 ± 2.1 to 4.5 ± 1.1 (p<0.001). Patient-reported pain and pruritus showed significant reduction (mean change: -4.4 points, p<0.001). Independent observer assessment demonstrated 51-75% improvement in 46.7% of cases (Kappa=0.84). Younger scars (≤1 year) showed superior response compared to older scars (VSS improvement: 5.8 ± 1.2 vs 4.9 ± 1.1, p=0.023). Transient adverse events included erythema (100%) and edema (93.3%), with mean recovery time of 5.8 ± 1.4 days. Conclusion: Fractional CO₂ laser therapy provides significant improvement in hypertrophic scars with a favorable safety profile and minimal downtime. Early intervention yields superior outcomes, suggesting optimal timing as an important consideration in treatment planning.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
2936 Views
341 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved